3,000+ experts discuss bioeconomy globallyMore than 3,000 attendees are participating in the Global Bioeconomy Summit, currently taking place virtually until 20th November. Today, the plenary program and the livestream of the conference kicked-off. more ➔
EU COVID-19 antibody ready for clinical trialsAs investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing. more ➔
COVID-19: Moderna reports promising interim resultsAfter BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%. more ➔
Evotec expanding at Milton Park campus Evotec SE is set to expand the company’s existing campus in Milton Park/Abingdon, UK, into a major, fully-integrated drug discovery and development centre. more ➔
Pfizer/BioNTech sign vaccine contract with EC Pfizer and Biontech SE have reached an agreement with the European Commission to supply 200 million doses of their mRNA-based COVID-19 vaccine candidate. more ➔
1,800+ experts will join the Global Bioeconomy SummitMore than 1,800 attendees already registered for the Global Bioeconomy Summit 2020. The conference takes place virtually from November 16 to 20. more ➔
BioNTech reports high efficacy of COVID-19 vaccineInterim data on BioNtech’s/Pfizer’s COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA. more ➔
Vifor Pharma inks $340m deal with Angion Biomedica Inc.Swiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedica’s experimental kidney drug ANG-3777. more ➔
Cell and gene therapy specialist Minaris expandingJapanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia. more ➔
Protein Brewery raise €22m in Series ALead investor Novo Growth has led a €22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein. more ➔
